Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study
Lenvatinib combined with PD-1 inhibitor significantly improves the survival of HCC beyond oligometastasis. For patients with HAIC, there was obviously significance between Len and Len+PD-1 groups.
Authors
- Ruixia Li (ORCID: https://orcid.org/0000-0002-0179-1807)
- Murong Wang
- Xiaohui Wang (ORCID: https://orcid.org/0000-0003-0544-2599)
- Jinhua Huang (ORCID: https://orcid.org/0000-0003-2960-6148)
- Hui Li (ORCID: https://orcid.org/0000-0002-4611-7808)
- Qunfang Zhou (ORCID: https://orcid.org/0000-0002-2533-3851)
- Feng Duan
- Mingyu Liu (ORCID: https://orcid.org/0000-0001-9905-4399)
- Wei Wang (ORCID: https://orcid.org/0000-0003-1568-222X)
Institutions
- Sun Yat-sen University (CN)
- Chinese PLA General Hospital (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Hunan Provincial People's Hospital (CN)
- Jinzhou Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/itt.s477972
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.37
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation